E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
If approved, BOTOX Cosmetic would become the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the US.
imphoenix82
AbbVie has received approval from the European Commission (EC) for RINVOQ (upadacitinib; 15 mg and 30 mg, once daily) to treat adults and adolescents aged 12 years and older with severe alopecia areata (AA). Alopecia areata is an autoimmune disorder that causes unpredictable hair loss, ranging from small bald patches on the scalp to complete […]
imphoenix82
AbbVie’s TEPKINLY (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific antibody-based therapy approved in Europe for second-line treatment of relapsed or refractory follicular lymphoma, providing a chemotherapy-free treatment option.
imphoenix82
AbbVie has received a positive CHMP opinion for upadacitinib (RINVOQ) to treat adults and adolescents with severe alopecia areata and non-segmental vitiligo, with a final European Commission decision expected in the coming months.
imphoenix82
AbbVie has received two European Commission (EC) approvals: MAVIRET has been approved for the treatment of acute hepatitis C virus (HCV) infection in adults and children aged three years and older, while SKYRIZI’s indication has been expanded to include children and adolescents aged six years and older with moderate to severe plaque psoriasis.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
